Curated News: Medical Meetings

Filters close
29-May-2024 9:00 AM EDT
Race and social vulnerability impact glycemic control in people with diabetes
Endocrine Society

People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
GLP-1 has the power to change taste sensitivity in women with obesity
Endocrine Society

Semaglutide improved taste sensitivity, changed gene expression in the tongue that’s responsible for taste perception, and changed the brain’s response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

29-May-2024 9:00 AM EDT
Prediabetes raises Mexicans’ risk of dying prematurely of heart or kidney disease
Endocrine Society

Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

Released: 1-Jun-2024 9:00 AM EDT
Childhood sedentariness may cause premature liver damage in young adulthood
Endocrine Society

Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, a new study finds. The research findings will be presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass and published in Nature’s npj Gut and Liver.

29-May-2024 9:00 AM EDT
Insurance often denies GLP-1 medications for teens with type 2 diabetes, obesity
Endocrine Society

Health insurance companies often deny coverage for new medications that treat children and teens with obesity and type 2 diabetes, meaning many patients who need treatment are unable to afford it, according to a study presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

Released: 1-Jun-2024 8:05 AM EDT
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

31-May-2024 8:00 AM EDT
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Released: 31-May-2024 8:15 AM EDT
Mount Sinai Experts Present Research at SLEEP 2024
Mount Sinai Health System

Sleep medicine experts available for interview on breaking and trending news about obstructive sleep apnea, CPAP, and more

Newswise: Dana-Farber researchers uncover disparities in lived experiences for patients and physicians
29-May-2024 8:05 AM EDT
Dana-Farber researchers uncover disparities in lived experiences for patients and physicians
Dana-Farber Cancer Institute

Four teams of Dana-Farber Cancer Institute investigators have found that people experience discrimination and bias in different ways and in more realms of cancer care than previously understood. The findings, in different studies, suggest that oncology professionals and the systems they work in have more work to do to adapt to the realities of increasing diversity and inclusion, not only in the patient population but also in the oncology workforce.

Newswise: American Cancer Society Researchers Presenting Key Studies at 2024 ASCO Meeting
Released: 29-May-2024 9:05 AM EDT
American Cancer Society Researchers Presenting Key Studies at 2024 ASCO Meeting
American Cancer Society (ACS)

Scientists from the American Cancer Society (ACS) are presenting important research studies at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024.

Newswise: RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
Released: 29-May-2024 5:30 AM EDT
RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
Mount Sinai Health System

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

Released: 24-May-2024 4:05 PM EDT
Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations
Roswell Park Comprehensive Cancer Center

New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.

Newswise: Internationally Trained Female Oncologists Face Many Discrimination Challenges in the U.S.
Released: 23-May-2024 7:05 PM EDT
Internationally Trained Female Oncologists Face Many Discrimination Challenges in the U.S.
Sylvester Comprehensive Cancer Center

ASCO: A new study highlights workplace discrimination reported by internationally trained female oncologists. Dr. Coral Olazagasti will present study findings that showed female oncologists reported much higher levels of gender or race/ethnicity-based discrimination than their male counterparts.

Newswise: Quadruple Therapies and the Future of Multiple Myeloma Treatment
Released: 23-May-2024 7:05 PM EDT
Quadruple Therapies and the Future of Multiple Myeloma Treatment
Sylvester Comprehensive Cancer Center

ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?

Newswise: Most young women treated for breast cancer can have children, study shows
23-May-2024 1:05 PM EDT
Most young women treated for breast cancer can have children, study shows
Dana-Farber Cancer Institute

New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.

Released: 21-May-2024 10:05 AM EDT
ENDO 2024 press conferences to highlight male birth control, anti-obesity medications
Endocrine Society

Researchers will delve into emerging research in diabetes, obesity, reproductive health and other aspects of hormone health during the Endocrine Society’s ENDO 2024 news conferences June 1-4.

Newswise: IU School of Medicine researchers to present respiratory therapy advancements at ATS 2024
Released: 17-May-2024 9:05 AM EDT
IU School of Medicine researchers to present respiratory therapy advancements at ATS 2024
Indiana University

Researchers will showcase promising respiratory disease research at the American Thoracic Society (ATS) 2024 International Conference and ATS 2024 Respiratory Innovation Summit (RIS), May 17-22 in San Diego, California.

Newswise: New imaging software improves lung diagnosis for 30% of patients who can't tolerate contrast dye; has added diagnostic benefits for all patients
Released: 17-May-2024 8:05 AM EDT
New imaging software improves lung diagnosis for 30% of patients who can't tolerate contrast dye; has added diagnostic benefits for all patients
Corewell Health

For up to 30% of patients who are allergic to medical contrast dye or have a dye restriction because of other health conditions, they might find that it takes longer to get a diagnosis when it comes to life-threatening lung issues such as pulmonary embolism.



close
2.93528